Actelion Ltd.’s experimental drug macitentan has a “very high” probability of success in a clinical trial that will be critical for the company’s future, Chief Executive Officer Jean-Paul Clozel said. Data from a late-stage trial of the medicine, a successor to Actelion’s top-selling lung drug Tracleer, will “realistically” be released in the second quarter, Clozel said in an interview yesterday in San Francisco. “What is important for us is to do everything in order for the trial to succeed,” such as monitoring the quality of data collection, Clozel said. “We are working on making this thing work.”
